NUR 641E Final Exam Newest 2025/2026
Questions and Correct Answers Graded
A+|Assured Success|Brand New Version
medication safety organizations - CORRECT ANSWER-ISMP
-IOM
-Joint Commission
-NCC MERP
-FDA Safe Use Initiative
,Absorption - CORRECT ANSWERfrom the administration site either directly or
indirectly into the blood/plasma
Distribution - CORRECT ANSWERReversibly or irreversibly move from
bloodstream into the interstitial and intracellular fluid
Metabolism - CORRECT ANSWERBiotransformed via hepatic metabolism or by
other tissues
Elimination - CORRECT ANSWERLastly, the drug and its metabolites are
eliminated from the body
IV - CORRECT ANSWER-highest bioavailability
-bypasses absorption
-*avoids first pass in the liver*
rectal - CORRECT ANSWER-erratic and variable absorption
4-5 - CORRECT ANSWERSS achieved in _-_ half lives
,Half-life - CORRECT ANSWER-how long it takes for drug to be excreted from
the body
-determines frequency of administration
-predicts how long toxic effects can last
first-order (linear) pharmacokinetics - CORRECT ANSWERmetabolism is
directly proportional to the free concentration of the drug
zero-order (nonlinear) pharmacokinetics - CORRECT ANSWERdrug is
metabolized at a constant rate per unit of time
CYP3A4 substrates - CORRECT ANSWERmay have decreased activity if any
CYP3A4 inducer drugs are used along with it
Discovery - CORRECT ANSWERlaboratory research to develop the new drug
Preclinical research - CORRECT ANSWERanimal testing for safety
, Phase I - CORRECT ANSWERclinical research on healthy human subjects to
assess medication PK
Phase II - CORRECT ANSWERclinical research in humans primarily for
medication safety usually in a population for which the treatment is intended
Phase III - CORRECT ANSWERclinical research in humans comparing the new
drug to accepted medications or placebo for efficacy and safety
Phase IV - CORRECT ANSWERpost marketing surveillance. Reporting of
adverse effects not identified in earlier clinical studies
pharmacological ADR - CORRECT ANSWER-80-90% of ADRs
-an extension of the pharmacological affect of the drug
-ex. overdose
idiosyncratic ADR - CORRECT ANSWER-separate from the pharmacological
affect of the drug
-commonly immune mediated response
Questions and Correct Answers Graded
A+|Assured Success|Brand New Version
medication safety organizations - CORRECT ANSWER-ISMP
-IOM
-Joint Commission
-NCC MERP
-FDA Safe Use Initiative
,Absorption - CORRECT ANSWERfrom the administration site either directly or
indirectly into the blood/plasma
Distribution - CORRECT ANSWERReversibly or irreversibly move from
bloodstream into the interstitial and intracellular fluid
Metabolism - CORRECT ANSWERBiotransformed via hepatic metabolism or by
other tissues
Elimination - CORRECT ANSWERLastly, the drug and its metabolites are
eliminated from the body
IV - CORRECT ANSWER-highest bioavailability
-bypasses absorption
-*avoids first pass in the liver*
rectal - CORRECT ANSWER-erratic and variable absorption
4-5 - CORRECT ANSWERSS achieved in _-_ half lives
,Half-life - CORRECT ANSWER-how long it takes for drug to be excreted from
the body
-determines frequency of administration
-predicts how long toxic effects can last
first-order (linear) pharmacokinetics - CORRECT ANSWERmetabolism is
directly proportional to the free concentration of the drug
zero-order (nonlinear) pharmacokinetics - CORRECT ANSWERdrug is
metabolized at a constant rate per unit of time
CYP3A4 substrates - CORRECT ANSWERmay have decreased activity if any
CYP3A4 inducer drugs are used along with it
Discovery - CORRECT ANSWERlaboratory research to develop the new drug
Preclinical research - CORRECT ANSWERanimal testing for safety
, Phase I - CORRECT ANSWERclinical research on healthy human subjects to
assess medication PK
Phase II - CORRECT ANSWERclinical research in humans primarily for
medication safety usually in a population for which the treatment is intended
Phase III - CORRECT ANSWERclinical research in humans comparing the new
drug to accepted medications or placebo for efficacy and safety
Phase IV - CORRECT ANSWERpost marketing surveillance. Reporting of
adverse effects not identified in earlier clinical studies
pharmacological ADR - CORRECT ANSWER-80-90% of ADRs
-an extension of the pharmacological affect of the drug
-ex. overdose
idiosyncratic ADR - CORRECT ANSWER-separate from the pharmacological
affect of the drug
-commonly immune mediated response
